20:13 , May 30, 2017 |  BC Extra  |  Company News

Protagonist soars on Janssen IBD deal

Oral peptide therapeutic company Protagonist Therapeutics Inc. (NASDAQ:PTGX) jumped $3.60 (44%) to $11.82 on Tuesday after it granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to co-develop and co-promote...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Allergan deal

The MedImmune LLC unit of AstraZeneca granted Allergan exclusive, worldwide rights to develop and commercialize MEDI2070, a human mAb against IL-23. The candidate is in a Phase IIb trial to treat moderate to...
07:00 , Oct 3, 2016 |  BC Extra  |  Company News

AZ grants Allergan rights to anti-IL-23 mAb

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Allergan plc (NYSE:AGN) exclusive, worldwide rights to MEDI2070, a human mAb against interleukin-23 (IL-23). The candidate is in a Phase IIb trial to treat moderate...
07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer IL-23; CD40 Mouse studies suggest combination therapy with IL-23 and CD40 mAbs could be more effective...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Amgen, AstraZeneca deal

Amgen and AstraZeneca partnered to jointly develop and commercialize five of Amgen's human mAbs in its inflammation portfolio. The deal includes anti-IL17R mAb brodalumab (formerly AMG 827), which is slated to begin Phase III...
07:00 , Apr 9, 2012 |  BioCentury  |  Strategy

Divvying up skill sets

AstraZeneca plc's deal for five clinical mAbs from Amgen Inc.'s inflammation and pulmonary portfolio puts the pharma close to its goal of getting 40% of its pipeline from external sources. For Amgen, last week's partnership...
01:09 , Apr 3, 2012 |  BC Extra  |  Top Story

Amgen partners five mAbs with AZN

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to jointly develop and commercialize five of Amgen's mAbs in its inflammation portfolio. The deal includes anti- IL17R mAb brodalumab (formerly AMG 827), which is slated...